Hepatitis C market rivals Merck & Co and Roche in marketing pact for newly-approved boceprevir
US drug giant Merck (NYSE: MRK) has entered into agreements with Swiss major Roche (SIX: ROG), through their respective subsidiaries, to improve treatment, diagnosis and awareness of chronic hepatitis C (HCV) infection in developed and emerging markets. The two companies have been long-time rivals in this market sector with their older drugs.
In addition, researchers affiliated with both companies will collaborate to examine novel combinations of marketed and investigational medicines from both organizations to expedite the availability of potential new treatment regimens for patients with HCV. Financial terms of the accord were not revealed.
Deal includes Victrelis promotion
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze